Hao W-J, Zong H-T, Cui Y-S, Zhang Y
Urology Department, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China.
Transplant Proc. 2012 Dec;44(10):2955-60. doi: 10.1016/j.transproceed.2012.05.085.
The objective of this study was to compare efficacy and safety of alemtuzumab, antithymocyte globulin (ATG), and daclizumab for induction therapy in organ transplantation.
We searched PUBMED, EMBASE, and Cochrane databases to identify randomized controlled trials that compared alemtzumab, ATG, and daclizumab for induction therapy in kidney as well as pancreas transplantation. According to the inclusion criteria, the collected data included general characteristics of the studies and their major outcomes. The meta-analysis was performed using RevMan 5.0.25 software.
We identified 9 studies involving 777 patients. No differences between alemtuzumab, daclizumab, and ATG were observed in terms of patient survival, graft survival, or acute rejection episodes at a 24-month follow-up (P = .62, P = .55, and P = .08, respectively). Infections within 36 months were greater between the alemtuzumab and the ATG group (P = .03). There was no significant difference in terms of infection at 24 months.
Alemtuzumab and daclizumab appeared to be as effective as ATG for induction therapy in kidney transplantation at a follow-up of 24 months. However, alemtuzumab showed a lower rate of infection at 36 months compared with ATG.
本研究旨在比较阿仑单抗、抗胸腺细胞球蛋白（ATG）和达利珠单抗在器官移植诱导治疗中的疗效和安全性。
我们检索了PUBMED、EMBASE和Cochrane数据库，以确定比较阿仑单抗、ATG和达利珠单抗在肾移植和胰腺移植诱导治疗中的随机对照试验。根据纳入标准，收集的数据包括研究的一般特征及其主要结果。使用RevMan 5.0.25软件进行荟萃分析。
我们确定了9项涉及777例患者的研究。在24个月的随访中，阿仑单抗、达利珠单抗和ATG在患者生存率、移植物生存率或急性排斥反应发生率方面未观察到差异（分别为P = 0.62、P = 0.55和P = 0.08）。阿仑单抗组和ATG组在36个月内的感染率更高（P = 0.03）。在24个月时，感染方面没有显著差异。
在24个月的随访中，阿仑单抗和达利珠单抗在肾移植诱导治疗中似乎与ATG一样有效。然而，与ATG相比，阿仑单抗在36个月时的感染率较低。
Zotero 插件